Proper Joint Care Cardiovascular health Immunity Allergy

HOME > Research

Visitor:725


Cardiovascular health

Animal Study(16):
In an animal model of cardiovascular disease, Beck used the Watanabe strain of rabbits and administered the following to each group: one group received no milk and no drug (control group), one group received the cholesterol-lowering drug Mevacor® and one group received S100 Milk(16). The Watanabe rabbit has a defective gene encoding the receptor for LDL; as a result, they lack the main mechanism for clearing LDL-associated cholesterol from the bloodstream. Even when fed conventional, low-fat rabbit diets, Watanabe rabbits develop severe hyperlipidemia and subsequently severe atherosclerosis. This well accepted, standard animal model was selected and used to compare the effects of S100 Milk and the cholesterol-lowering drug Mevacor®. After 18 and 36 weeks’ feeding, comparisons of the effects on lowering blood lipids and levels of atherosclerosis were determined. S100 Milk had similar cholesterol lowering properties when compared with the cholesterol-lowering drug Mevacor®(Table 1). However, S100 Milk was shown to significantly inhibit the development of coronary atherosclerosis and reduce the formation of fibrous plaques in arteries, while the above effects from the cholesterol-lowering drug Mevacor® were not seen (Fig. 1).

Because S100 Milk has significant anti-inflammatory effects(17), the inhibitory effect on the formation of fibrous plaques may be due, in part to the anti-inflammatory factors (AIF) shown to be in S100 Milk, rather than just simply due to lowering cholesterol levels in the blood.

Total Cholesterol, mg/dL
Time (weeks) Control S100 Milk Mevacor®
-2 101.38 ± 1.91 97.13 ± 1.52 101.50 ± 2.50
0 139.00 ± 5.60 135.50 ± 1.36 124.38 ± 1.36
4 561.00 ± 13.58 527.13 ± 1.71 511.50 ± 1.81
8 653.25 ± 10.64 626.50 ± 2.72 617.50 ± 1.38
12 679.63 ± 9.38 653.63 ± 1.51 648.25 ± 1.28
16 692.50 ± 8.66 665.13 ± 1.23 656.75 ± 0.92
18 724.25 ± 1.65 672.00 ± 1.08 664.75 ± 1.25
20 673.25 ± 1.97 667.00 ± 1.96 660.00 ± 1.29
24 672.25 ± 2.17 667.75 ± 1.80 660.50 ± 1.55
28 673.25 ± 2.32 668.00 ± 2.20 660.00 ± 2.48
32 672.75 ± 0.85 668.25 ± 1.89 661.50 ± 2.78
36 672.50 ± 2.10 667.00 ± 2.12 662.00 ± 2.35
18 week AUC 2,315.8 ± 127.9 2,199.3 ± 103.4 2,206.6 ± 101.7
36 week AUC 4,719.0 ± 6.4 4,580.5± 20.5* 4,621.0± 30.8**

Table 1. The effect of S100 Milk and Mevacor® on reducing cholesterol in the blood. Both S100 Milk and Mevacor® showed the significant differences compared to the control group(16). AUC: Area Under Curve (△mg/dL*weeks) *P= 0.0039 vs Control **P= 0.0268 vs Control

Fig. 1. S100 Milk shows statistically significant inhibition of the formation of coronary plaque while the Mevacor® group did not show significant inhibition(16).

 

Immune today, healthy everyday.
回上一頁置上

These statements have not been evaluated by the Food and Drug Administration.

The products mentioned here are not intended to diagnose, treat, cure or prevent any disease.